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Abstract
Background: Left ventricular non-compaction (LVNC) is an unclassified cardiomyopathy and there is no consensus
on the diagnosis of LVNC. The aims of this study were to establish quantitative methods to diagnose LVNC using
cardiovascular magnetic resonance (CMR) and to suggest refined semi-quantitative methods to diagnose LVNC.
Methods: This retrospective study included 145 subjects with mild to severe trabeculation of the left ventricle
myocardium [24 patients with isolated LVNC, 33 patients with non-isolated LVNC, 30 patients with dilated
cardiomyopathy (DCM) with non-compaction (DCMNC), 27 patients with DCM, and 31 healthy control subjects with
mild trabeculation]. The left ventricular (LV) ejection fraction, global LV myocardial volume, trabeculated LV
myocardial volume, and number of segments with late gadolinium enhancement were measured. In addition, the
most prominent non-compacted (NC), compacted (C), normal mid-septum, normal mid-lateral wall, and apical
trabeculation thicknesses on the end-diastolic frames of the long-axis slices were measured.
Results: In the patients with isolated LVNC, the percentage of trabeculated LV volume (TV%, 42.6 ± 13.8 %) relative to
total LV myocardial volume was 1.4 times higher than in those with DCM (30.3 ± 14.3 %, p < 0.001), and 1.7 times
higher than in the controls (24.8 ± 7.1 %, p < 0.001). However, there was no significant difference in TV% between the
isolated LVNC and DCMNC groups (47.1 ± 17.3 % in the DCMNC group; p = 0.210). The receiver operating characteristic
curve analysis using Jenni’s method for CMR classification as the standard diagnostic criteria revealed that a value of
TV% above 34.6 % was predictive of NC with a specificity of 89.7 % (CI: 74.2 - 98.0 %) and a sensitivity of 66.1 % (CI: 52.6
- 77.9 %). A value of NC/septum over 1.27 was considered predictive for NC with a specificity of 82.8 % (CI: 64.2 -
94.2 %) and a sensitivity of 57.6 % (CI: 44.1 - 70.4 %). In addition, a value of apex/C above 3.15 was considered
predictive of NC with a specificity of 93.1 % (CI: 77.2 - 99.2 %) and a sensitivity of 69.5 % (CI: 56.1 - 80.8 %).
Conclusions: A trabeculated LV myocardial volume above 35 % of the total LV myocardial volume is diagnostic for
LVNC with high specificity. Also, the apex/C and NC/septum ratios could be useful as supplementary diagnostic criteria.
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Background
Left ventricular non-compaction (LVNC) is an unclassified
cardiomyopathy characterized by an extremely thick
endocardial layer with prominent trabeculation and a thin
epicardial layer [1]. LVNC has been linked to several
genetic mutations and, in adult forms of LVNC, it is
predominantly an autosomal-dominant inheritance pattern
[2, 3]. Although LVNC can occur in the absence of other
coexisting cardiac abnormalities [4], it can also be
associated with various forms of congenital heart diseases,
particularly stenotic lesions of the left ventricular outflow
tract, Ebstein’s anomaly, and tetralogy of Fallot [5], and in
addition, there are some relationships between LVNC and
neuromuscular disorders [6]. It is widely known that the
major clinical manifestations of LVNC are heart failure,
thrombo-embolism, and arrhythmia [7, 8].
There have been many attempts to establish standard
diagnostic criteria in LVNC using various imaging
modalities. At present, Jenni et al.’s echocardiographic
criteria of a ratio over 2.0 between the thickness of the
non-compacted and compacted myocardial layers in
systole are widely recognized as the standard diagnostic
criteria for LVNC [4]. Echocardiography is useful for the
diagnosis of LVNC; however, there are concerns about
overestimated diagnosis of LVNC due to the high sensi-
tivity of the echocardiographic criteria [9, 10]. Recently,
cardiovascular magnetic resonance (CMR) is becoming
more widely used in the assessment of LVNC [11]. CMR
allows more accurate and reliable evaluation of the extent
of non-compacted myocardium than does two-
dimensional echocardiography and provides supplemen-
tary morphological information, particularly in the left
ventricle (LV) apex and lateral wall [12]. Petersen et al.
suggested a semi-quantitative method to diagnose LVNC
using CMR [13]. They assessed each of three diastolic
long-axis cine MR images, and a maximum ratio of non-
compacted to compacted myocardial thicknesses (NC/C
ratio) greater than 2.3 is considered diagnostic for LVNC.
However, LVNC with apical involvement could not be
assessed with their criteria because of the thin apical com-
pact myocardium. Jacquier et al. proposed a quantitative
method to diagnose LVNC by measuring trabeculated LV
mass [14]. The trabeculated LV mass was calculated by
subtracting the compacted LV mass from the total LV
mass. Based on this, a percentage of trabeculated LV mass
over 20 % was considered as the diagnostic cut-off.
Even when using high-contrast imaging modalities
such as CMR, however, there are still concerns about
the overdiagnosis of LVNC [15, 16]. In addition, there
has been no consensus in the diagnosis of LVNC.
Therefore, the purposes of this study were to determine
quantitative diagnostic criteria for LVNC using CMR and
to suggest refined semi-quantitative methods to diagnose
LVNC, especially in cases with apical involvement.
Methods
This study was approved by the Samsung Medical
Center Institutional Review Board; informed consent
was waived for this retrospective study.
Study population
We queried the clinical and CMR databases at our
institute for patients diagnosed with cardiomyopathy
between August 2009 and December 2013. Of a total of
11,997 patients diagnosed with cardiomyopathy, we
extracted consecutive patients who had CMR reports
that included descriptions of non-compaction. We also
included subjects with mildly or moderately increased
LV trabeculation (hypertrabeculation) measuring more
than 5 mm in thickness and NC/C ratios of 1.0–2.3 any-
where in the myocardial segments on the CMR images.
We enrolled the LVNC group according to two inclu-
sion criteria: CMR images with a distinct two-layered
appearance of trabeculated and compacted myocardium
and the fulfillment of Petersen et al.’s CMR criteria for
the diagnosis of LVNC. As dilated cardiomyopathy
(DCM) is a potential differential diagnosis for LVNC, we
retrospectively enrolled two other groups: DCM with
LVNC and DCM with hypertrabeculation. We classi-
fied patients with DCM into two groups according to
Petersen et al.’s CMR criteria. The diagnosis of DCM
was made on the basis of impaired global LV function
with an ejection fraction of less than 40 % on CMR,
LV chamber dilatation, and the exclusion of other
causes of LV dysfunction.
The remaining subjects were a healthy control group
without a history of cardiovascular symptoms, valvular
heart disease, coronary artery disease, or cardiomyopathy.
We randomly extracted sex- and age-matched subjects for
the control group. Finally, the study population comprised
of a total of 145 patients divided into the following five
subgroups: patients for whom a diagnosis of LVNC was
established based on Petersen et al.’s CMR criteria (group
1 for isolated LVNC [INC], n = 24; group 2 for accompan-
ied with other diseases [non-isolated type, NINC], n = 33;
group 3 for patients with DCM with LVNC
[DCMNC], n = 30; group 4 for patients with DCM
and hypertrabeculation, n = 27; and group 5 for the
healthy control group with hypertrabeculation, n = 31)
(Table 1).
The distribution of the percentages of trabeculated LV
volumes and the various ratios in the long-axis cine im-
ages were studied in the five different groups. To ensure
the efficient measurement of the LV trabeculated areas,
we excluded two subjects with low CMR image quality
due to arrhythmic or respiratory artifacts. All clinical
and demographic data were obtained from the electronic
medical records.
Choi et al. Journal of Cardiovascular Magnetic Resonance  (2016) 18:24 Page 2 of 13
Characteristics of patients
We reviewed the electronic medical records of the patients
for diabetes, hypertension, dyslipidemia, congestive heart
failure (CHF), coronary artery disease (CAD), and any
arrhythmias. Diabetes was defined as a patient who had
been diagnosed with diabetes or was taking glucose-
lowering medication. Hypertension was defined as a
diagnosis of hypertension or patients with systolic blood
pressure ≥ 140 mmHg or diastolic blood pressure ≥
90 mmHg. Dyslipidemia was defined by laboratory findings
(total cholesterol > 200 mg/dL or low-density lipoprotein
cholesterol > 130 mg/dL). To assess arrhythmia, we
reviewed the patients’ electrocardiographic findings, and
any arrhythmia from atrial fibrillation to ventricular tachy-
cardia was included.
Acquisition of CMR data
All patients underwent cardiac MRI using a 1.5 T
scanner (Magnetom Avanto, Syngo MR version B17;
Siemens Medical Solutions, Erlangen, Germany) with a
32-channel phased-array receiver coil during repeated
breath-holds. After localization, cine images of LV were
acquired using a steady-state free-precession sequence
in four-, two-, and three-chamber views and in short-
axis views to obtain 20–30 contiguous short-axis slices
to include the entire LV with a slice thickness of 6 mm
and gaps of 4 mm (Fig. 1). In cases with arrhythmia or
breathing difficulty, fast cine MRI with a temporal
parallel acquisition technique (acceleration factor: 3) was
used for cine MRI.
Standard late gadolinium-enhanced imaging was
performed using a phase-sensitive inversion-recovery tech-
nique 15 min after an injection of 0.2 mmol/kg gadobutrol
(Gadovist; Bayer Healthcare, Berlin, Germany) using
contiguous short-axis image acquisition of 10 to 12 slices at
6-mm thickness with 4-mm interslice gaps. Inversion delay
times were typically 280 to 360 msec.
CMR analysis
Non-compaction distribution analysis
The distribution of LVNC was assessed by the qualitative
analysis of all 17 American Heart Association segments
for the presence of a distinct two-layered appearance. A
segment was regarded as having hypertrabeculation if
the trabeculated to compacted ratio (NC/C ratio) in
diastole was higher than 1.0. In addition, an NC/C ratio
over 2.3 is considered as non-compaction. We excluded
segments where the trabeculated area was less than 50 %
of the total thickness.
We also classified the distribution of trabeculation into
three patterns: the global, apical, and non-apical types.
The global type was defined as having over ten two-
Table 1 Patient characteristics in five groups
Variables Isolated LVNC (n = 24) Non-isolated LVNC (n = 33) DCMNC (n = 30) DCM (n = 27) Control (n = 31)
Age, years 51.2 ± 12.8 55.1 ± 16.5 (P = 0.179) 53.0 ± 14.1 (P = 0.688) 59.2 ± 15.8 (P = 0.026) 55.4 ± 7.8 (P = 0.137)
Sex, male (%) 50.0 57.6 60.0 70.4 74.2
Height, cm 164.7 ± 7.5 167.0 ± 9.0 (P = 0.303) 162.3 ± 8.2 (P = 0.280) 164.4 ± 10.5 (P = 0.962) 166.2 ± 8.7 (P = 0.518)
Weight, kg 62.9 ± 12.3 65.2 ± 10.7 (P = 0.593) 63.4 ± 13.7 (P = 0.896) 63.3 ± 14.1 (P = 0.992) 68.0 ± 12.2 (P = 0.166)
BSA, m2 1.68 ± 0.19 1.73 ± 0.17 (P = 0.460) 1.67 ± 0.18 (P = 0.501) 1.69 ± 0.23 (P = 0.879) 1.76 ± 0.19 (P = 0.205)
SBP, mmHg 117.9 ± 11.6 118.0 ± 17.2 (P = 0.935) 114.0 ± 18.7 (P = 0.061) 113.0 ± 15.1 (P = 0.274) 127.9 ± 13.0*
DBP, mmHg 66.7 ± 8.4 67.7 ± 10.8 (P = 0.446) 68.8 ± 11.3 (P = 0.500) 67.6±12.0 (P = 0.992) 75.3 ± 8.5*
TC, mg/dL 195.6 ± 46.6 168.8 ± 30.6 (P = 0.028) 170.7 ± 41.2 (P = 0.023) 165.1±35.2 (P = 0.020) 197.1 ± 33.0 (P = 0.812)
TG, mg/dL 148.5 ± 147.0 117.1 ± 59.2 (P = 0.992) 125.5 ± 99.1 (P = 0.726) 118.0±82.2 (P = 0.725) 125.6 ± 72.1 (P = 0.926)
LDL-C, mg/dL 119.6 ± 36.0 104.9 ± 33.3 (P = 0.114) 105.7 ± 28.9 (P = 0.105) 94.7 ± 27.5 (P = 0.018) 127.0 ± 28.4 (P = 0.441)
HDL-C, mg/dL 58.7 ± 19.6 51.0 ± 12.2 (P = 0.166) 46.5 ± 15.2 (P = 0.038) 52.3 ± 23.9 (P = 0.080) 53.0 ± 14.1 (P = 0.244)
FBS, mg/dL 99.3 ± 11.7 104.9 ± 20.1 (P = 0.321) 122.6 ± 52.6 (P = 0.052) 115.0 ± 45.3 (P = 0.253) 101.1 ± 14.6 (P = 0.634)
Hypertension (%) 12.5 18.2 (P = 0.720) 26.7 (P = 0.310) 25.9 (P = 0.300) 22.6 (P = 0.486)
Diabetes (%) 8.3 15.2 (P = 0.687) 20.0 (P = 0.277) 33.3** 6.5 (P = 1.000)
Dyslipidemia (%) 41.7 33.3 (P = 0.585) 16.7 (P = 0.066) 18.5 (P = 0.123) 45.2 (P = 1.000)
CHF (%) 0 18.2** 46.7** 59.3** 0.0
CAD (%) 0 18.2 ** 3.3 (P = 1.000) 7.4 (P = 0.492) 3.2 (P = 1.000)
CVA/TIA (%) 0 0 3.3 (P = 1.000) 11.1 (P = 0.238) 0.0
Arrhythmia (%) 0 30.3** 20.0** 18.5 (P = 0.052) 0.0
Note- Data are mean ± standard deviation (SD)
BSA body surface area, CAD coronary artery disease, CHF congestive heart failure, CVA cerebrovascular accident, DBP diastolic blood pressure, FBS fasting blood
sugar, HDL high density lipoprotein-cholesterol, LDL low density lipoprotein-cholesterol, SBP systolic blood pressure, TC total cholesterol, TG triglyceride, TIA transient
ischemic attack. P-value was calculated in comparison with values obtained from isolated LVNC patients and *p < 0.0125, **p < 0.05
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layered segments in total. The apical type was defined as
involving more than three segments in the apical level
(segments 13 through 17). The non-apical type was any
trabeculation that did not meet the definitions of the
global or apical types.
Semi-quantitative measurement
During the measurement of the most prominent tra-
beculation to compacted ratio in three long-axis views
as in Petersen’s CMR criteria [13], we also measured
mid-septum and mid-lateral wall thicknesses in dia-
stole. If apical trabeculation was present, the trabecu-
lated thickness was measured perpendicular to the
apex in diastole. We calculated the ratios of the
thickness of apical trabeculation to that of compacted
myocardium in the apical lateral segments (apex/C ra-
tio), the apical trabeculation to the septal wall thick-
ness (apex/septum ratio), the apical trabeculation to
the mid-lateral wall thickness (apex/mid-lateral ratio),
and the trabeculated myocardium to the mid-septal
wall thickness (NC/septum ratio) (Fig. 1). We calcu-
lated ratios from each of the three long-axis views,
and only the maximal ratio was then used for ana-
lysis. The end-systolic ratio of non-compacted to
compacted myocardial thickness was also measured
on short-axis cine images in systole.
Trabeculated volume measurement
Using short-axis cine images, we determined end-
diastolic frames when the cavity sizes were largest and
end-systolic frames when the cavity sizes were smallest.
Trabeculated volume measurements were performed on
the end-diastolic frames of each short-axis slice in the LV
stack. After we identified a distinct two-layered structure,
we manually measured the trabeculated area with a pic-
ture archiving and communication system (Centricity™
PACS, General Electric Healthcare Integrated IT Solu-
tions, Barrington, IL, USA). An endocardial border and
non-compacted layer border were drawn to include the
trabeculated area, and the papillary muscles were specific-
ally excluded from the measurement (Fig. 1). When the
papillary muscles were indistinguishable from trabecula-
tion, they were treated as trabeculation. The percentage of
trabeculated LV volume (TV%) relative to total LV
myocardial volume was calculated by the following
equation: ([trabeculated LV volume] ∕ [total LV myocardial
volume]) × 100. The trabecular volume index was
calculated by dividing the trabecular volume by the body
surface area (BSA).
The LV ejection fraction (LVEF), LV end-diastolic
volume (LVEDV), LV end-systolic volume (LVESV)
and LV myocardial mass were measured using an
Argus workstation (Siemens). LVEDVi was calculated
as LVEDV/BSA and LVESVi was calculated as
LVESV/BSA.
Wall thickening of compact myocardium in the non-
compaction areas was measured from the short-axis cine
images of the apical level using the following equation:
compact myocardial wall thickening = ([end-systolic
Fig. 1 Measurement of left ventricle non-compaction (LVNC) with CMR.
Illustration of the described method for measuring the trabeculated LV
area in a patient with isolated LVNC. The trabeculated LV area was
measured manually using a picture archiving and communication
system on an end-diastolic frame of each short-axis slice (a). An
endocardial border and non-compacted layer border were drawn
to include the trabeculated area, and the papillary muscles were
excluded from the measurement. We measured the most prominent
non-compacted to compacted ratio in three long-axis views and also
measured the mid-septal and mid-lateral walls and the apical
trabeculation thickness in diastole; all measurements were
performed perpendicular to the epicardium (b). A, apical
trabeculation; C, compacted myocardium for Petersen’s criteria;
ML, mid-lateral wall; NC, non-compacted area for Petersen’s
criteria; S, mid-septal wall
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compact wall thickness] − [end-diastolic compact wall
thickness])/[end-diastolic compact wall thickness].
We also assessed the number of myocardial segments
with late gadolinium enhancement (LGE). LGE was
defined as a signal intensity higher than three standard
deviations above the mean intensity of the region of
interest in the remote normal myocardium using semi-
quantitative software (QMass ES, Medis Medical Im-
aging Systems, Leiden, The Netherlands).
Statistical analysis
All continuous data are presented as means ± standard
deviations (SDs), and categorical data are presented as
percentages. The statistical analysis was performed using
SPSS for Windows 18.0 (IBM, Chicago, IL, USA).
Continuous data in the patient group characteristics
were compared by the Kruskal–Wallis non-parametric
tests; when results from these were significant, we com-
pared them by the Mann–Whitney U non-parametric
tests for post hoc analysis. In these cases, the Bonferroni
correction was applied to ensure an overall type I error
rate of 5 % and an adjusted P < 0.05/4 = 0.0125 was
considered significant. In addition, the categorical data
in the patient group characteristics were compared by
chi-square tests.
The interobserver reproducibility was assessed using
intraclass correlation and Bland–Altman analysis [17] by
calculating the bias (mean difference) and the 95 %
limits of agreement (1.96 times the SD around the mean
difference). To assess interobserver and intraobserver
consistency, a subset of cases (n = 20) was randomly se-
lected and measured by a second rater blinded to all
information.
We used receiver operating characteristics (ROC)
curves to determine the optimal cut-off values of the
trabeculated volume, apex/C, apex/septum, apex/mid-
lateral, and NC/septum ratios. A comparison of the
areas under the ROC curves was performed using the
method described by Hanley et al. [18]. Based on the
ROC curve analysis, we determined the optimal diagnostic
thresholds of each value to distinguish the highly trabecu-
lated myocardium (LVNC groups) from patients with a
normal amount of trabeculation (healthy control group).
As the frequency of LGE-positive segments was high in
the DCMNC and DCM groups, we analyzed the correl-
ation between the number of LGE segments and trabecu-
lated LV volume in the DCMNC and DCM groups.
Results
Characteristics of patients
The study population was comprised of 145 patients
and was homogeneous in its race and ethnicity, Asian
(Korean). All four groups were matched in terms of age
and sex, and all groups were also comparable in terms of
height, weight, and body surface area (Table 1).
The proportions of hypertension, diabetes, and
dyslipidemia did not differ significantly among the five
groups (Table 1). However, there were statistically differ-
ent proportions of CAD, CHF, arrhythmias, cerebrovas-
cular accidents (CVA), and transient ischemic attacks
(TIA) among the five groups. Compared with the other
three groups, the DCMNC and DCM patients had
greater incidences of diabetes (20–33 % versus 7–15 %),
CHF (47–59 % versus 0–18 %), and CVA/TIA (3–11 %
versus 0 %). In contrast, dyslipidemia was more common
in the LVNC and control groups than in the DCMNC
and DCM groups (33–45 % versus 17–19 %).
Arrhythmia was more common in the NINC, DCMNC
and DCM groups as compared with the INC and con-
trol groups (18–30 % versus 0 %). However, there
were no statistically significant differences in the inci-
dence of arrhythmia among the three groups.
In the INC group, only one patient among 24 was
diagnosed as having myotonic dystrophy. In the patients
with LVNC and accompanying heart diseases, there were
CADs including myocardial infarction (old, 9; acute, 1),
valvular heart diseases (n = 8; aortic regurgitation = 5,
mitral regurgitation = 3), arrhythmia (n = 10), congenital
heart diseases (n = 3), unclassified cardiomyopathy (n = 3),
hypertrophic cardiomyopathy (n = 2), and Marfan
syndrome (n = 1). We had four LVNC patients with ven-
tricular arrhythmia (ventricular fibrillation = 1, ventricular
tachycardia = 3) not associated other structural heart
diseases.
CAD, CHF, and arrhythmia were significantly more
frequent in the NINC group than in the INC group
(CAD, 18.2 % versus 0 %; CHF, 18.2 % versus 0 %;
arrhythmia, 30.3 % versus 0 %; Table 1).
There was no significant difference in N-terminal
pro-brain natriuretic peptide (NT-proBNP) between
INC group (40.5 ± 38.8 pg/mL) and control group
(34.8 ± 29.8 pg/mL) by Student t-test (p = 0.535).
Distribution of non-compacted area
The patterns of distribution of the trabeculation areas
with trabeculation thicknesses of more than 5 mm in the
American Heart Association’s 17-segment model were
almost similar among the groups. There were more basal
segments in the NINC group (54.5 %) than in the INC
group (33.3 %) (Fig. 2). In the control group, the
trabeculation involved less basal segments than in the
other groups. Also, the DCM group showed less
apical segment (70.4 %) involvement than other
groups (93.3 % - 100 %) did.
In our classification of the distribution of trabeculation
(NC/C > 1.0 and trabeculation thickness > 5 mm) in 57
LVNC patients, 25 were the global type (43.9 %), 30 were
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the apical type (52.6 %), and two were the non-apical
type (3.5 %). Of the 30 DCMNC cases, 22 were the
global type (73.3 %) and eight were the apical type
(26.7 %). Of the 27 DCM cases, five were the global type
(18.5 %), 19 were the apical type (70.4 %), and three were
non-apical type (11.1 %). Finally, of the 31 control cases,
one was the global type (3.2 %) and 30 were the apical
type (96.8 %) (Fig. 3). Interestingly, trabeculation was
absent in the LV apex (segment 17) in 9 (6.2 %) of 145
subjects (Fig. 3). Six (22.2 %) DCM patients, two (6.7 %)
DCMNC patients, and one (3.0 %) NINC patient showed
no apical trabeculation.
In 87 patients with LVNC (groups of INC, NINC,
DCMNC), severe trabeculation meeting Peterson’s
criteria of LVNC (NC/C > 2.3) was observed most
frequently in the segment 16 (77 %) followed by the
segment 17 (67.8 %), segment 13 (47.1 %), segment 15
(46 %), segment 12 (28.7 %), segment 11 (26.4 %), seg-
ment 10 (11.4 %), segment 7 (6.9 %), segment 1 (2.3 %),
segment 8 (1.1 %), and segment 5 (1.1 %) (Fig. 4).
Fig. 2 Distribution of left ventricular trabeculation (NC/C > 1.0 and trabeculation thickness > 5 mm) in all the patient groups according to the
American Heart Association 17-segment model (bull’s eye diagram). Control, normal subjects with hypertrabeculation; DCM, dilated cardiomyopathy
with hypertrabeculation; DCMNC, dilated cardiomyopathy with non-compaction; INC, isolated non-compaction; NINC, non-isolated non-compaction
Fig. 3 Types of LV non-compaction or hypertrabeculation on long-axis cine MR images. a Global type in a patient with isolated LVNC, b apical
type in a patient with non-isolated LVNC, c) non-apical type in a patient with DCM, d) global type with severe wall thinning (arrows) in the
compacted myocardium. Note absence of trabeculation in the apex (arrow) in the non-apical type (c)
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Semi-quantitative non-compaction criteria, LV volumes,
and LGE according to groups
In patients with LVNC, the NC/C ratios measured by
Petersen’s method [13] were significantly higher than
those in the DCM and control groups (Table 2). Also,
the same pattern was seen in the NC/septum, apex/C,
apex/septum, and apex/mid-lateral ratios. In addition,
all five of the ratios that we measured were statisti-
cally similar between LVNC and DCMNC groups.
In INC group, LVEDVi (77.6 ± 12.9 mL/m2) was 2.2
times lower than in DCMNC group (173.0 ± 56.4 mL/m2),
and similar to the control group (76.5 ± 8.8 mL/m2). In
INC group, LVESVi (27.7 ± 8.3 mL/m2) was 4.8 times
lower than in DCMNC group (132.8 ± 53.9 mL/m2), and
similar to the control group (25.7 ± 5.9 mL/m2) (Table 2).
The proportion of patients with LGE-positive
segments was 4.2 % (1/24) in the INC group. In the
NINC group, however, 45.5 % (15/33) of the patients
Fig. 4 Segmental distribution of LVNC (NC/C > 2.3) in 87 patients with LVNC. LVNC is most frequent in the apical segments and also distributed
in the inferior and lateral segments of the middle level of LV
Table 2 CMR measurements of left ventricle function, trabecular volume, and semi-quantitative diagnostic criteria
Variables Isolated LVNC (n = 24) Non-isolated LVNC (n = 33) DCMNC (n = 30) DCM (n = 27) Control (n = 31)
LVEF, % 64.7 ± 6.4 47.6 ± 17.0* 24.8 ± 9.2* 27.9 ± 10.1* 66.5 ± 5.9 (P = 0.430)
LVEDV, mL 131.1 ± 28.5 186.8 ± 60.9* 293.0 ± 120.2* 277.0 ± 92.7* 134.4 ± 22.9 (P = 0.722)
LVEDVi, mL/m2 77.6 ± 12.9 107.8 ± 33.6* 173.0 ± 56.4* 165.9 ± 57.8* 76.5 ± 8.8 (P = 0.754)
LVESV, mL 47.1 ± 17.0 101.0 ± 54.0* 225.6 ± 110.7* 203.9 ± 83.1* 45.5 ± 12.4 (P = 1.000)
LVESVi, mL/m2 27.7 ± 8.3 58.6 ± 31.2* 132.8 ± 53.9* 122.0 ± 51.0* 25.7 ± 5.9 (P = 0.635)
SV, mL 84.0 ± 16.7 85.8 ± 32.7 (p = 0.518) 67.4 ± 30.7* 73.0 ± 29.2 (P = 0.045) 89.0 ± 14.5 (P = 0.235)
NC/C ratioa 3.08 ± 0.80 2.90 ± 0.53 (p = 0.593) 2.92 ± 0.77 (P = 0.342) 1.71 ± 0.34* 1.40 ± 0.39*
NC/septum ratio 1.45 ± 0.28 1.37 ± 0.34 (p = 0.304) 1.52 ± 0.44 (P = 0.566) 1.07 ± 0.29* 0.93 ± 0.22*
Apex/C ratio 4.84 ± 1.89 3.57 ± 1.89 (p = 0.056) 3.26 ± 1.80* 1.25 ± 1.15* 1.96 ± 1.01*
Apex/septum ratio 2.28 ± 0.84 1.69 ± 0.96 (P = 0.023) 1.71 ± 0.95 (P = 0.065) 0.83 ± 0.89* 1.31 ± 0.73*
Apex/mid-lat ratio 4.53 ± 2.51 3.00 ± 1.70 (P = 0.048) 2.99 ± 1.69 (P = 0.049) 1.24 ± 1.18* 1.89 ± 0.99*
Trab. Vol., mL 32.1 ± 13.8 45.1 ± 15.3* 61.6 ± 25.5* 41.9 ± 18.4* 23.9 ± 6.9*
Trab. Vol., %LV 42.6 ± 14.8 44.2 ± 15.4 (p = 0.891) 47.1 ± 17.3 (P = 0.210) 30.3 ± 14.3* 24.8 ± 7.1*
C compacted, apex apical trabeculation thickness, LVNC left ventricular non-compaction, DCM dilated cardiomyopathy, DCMNC DCM with left ventricular non-compaction,
LVEF left ventricular ejection fraction, LVEDV left ventricular end-diastolic volume, LVESV left ventricular end-systolic volume, mid-lat mid-lateral wall thickness,
NC non-compacted, SV stroke volume, septum septal wall thickness, Trab. trabeculated, vol. volume. Values are mean ± SD. P-value was calculated in comparison with
values obtained from LVNC patients. *P < 0.013
aResults from analysis by the Petersen’s method
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had LGE-positive segments. The mean number of seg-
ments with LGE was 0.04 ± 0.20 in INC group. However,
there were statistically higher mean numbers of LGE-
positive segments in the NINC (2.7 ± 3.9, p < 0.001),
DCMNC (7.1 ± 5.1, p < 0.001), and DCM (6.3 ± 4.1, p <
0.001) groups. The trabeculated LV volume was positively
correlated with the number of LGE-positive segments
(Spearman ρ: 0.350; p = 0.008) (Fig. 5). In a subgroup ana-
lysis, the DCMNC group showed positive correlation be-
tween the number of LGE segments and trabeculated LV
volume (Spearman ρ: 0.396; p = 0.03). In the DCM group,
however, there was no correlation between the number of
LGE segments and trabeculated LV volume.
Correlation between trabeculated LV volume and LV
function measurements
In analyses of the INC group and the control group,
which had no other cardiac abnormalities, trabeculated
volume correlated positively with LVEDV (Spearman
ρ: 0.591; p = 0.006) and LVESV (Spearman ρ: 0.618;
p = 0.004) (Fig. 6). However, no correlation emerged
between trabeculated LV volume and LVEF in INC
and control groups.
In the DCMNC and DCM groups, trabeculated LV
volume correlated positively with LVEDV (Spearman
ρ: 0.556; p < 0.001) and LVESV (Spearman ρ: 0.555;
p < 0.001) and negatively with LVEF (Spearman ρ: −0.385;
p = 0.003) (Fig. 7). In results that were re-analyzed by
separating the groups, the trabeculated LV volume was
positively correlated with LVEDV (Spearman ρ: 0.755;
p < 0.001) and LVESV (Spearman ρ: 0.753; p < 0.001)
and negatively correlated with LVEF (Spearman ρ: −0.423;
p = 0.02) in the DCMNC group. In the DCM group, how-
ever, there were no significant correlations except with
LVEDV (Spearman ρ: 0.439; p = 0.022).
The percentage of trabeculated LV myocardial volume
was not significantly correlated with LVEF, LVEDV, or
LVESV in any of the groups. In the INC group, LVEF
under 55 % was found in only 8.3 % (2/24) of subjects.
The thickness of compacted myocardium in the
area of LVNC or hypertrabeculation was less than
2 mm in 91.7 % (22/24) of INC, 66.7 % (22/33) of
NINC, 86.7 % (26/30) of DCMNC, 70.4 % (19/27) of
DCM, 9.7 % (3/31) of control group (Fig. 3). There
was no significant difference in mean compacted wall
thickening among INC (0.77 ± 0.66), NINC (0.77 ±
0.51) and DCMNC (0.58 ± 0.58) (p = 0.3478) groups
by one-way analysis of variance (ANOVA).
Distribution of the percentage of trabeculated LV volume
and reproducibility
In the patients with INC, TV% (42.6 ± 13.8 %) was 1.4
times higher than that in DCM (30.3 ± 14.3 %, p <
0.001), and 1.7 times higher than that in the controls
(24.8 ± 7.1 %, p < 0.001) (Fig. 8 and Table 2). How-
ever, there were no significant differences in TV%
between the INC and DCMNC groups (DCMNC:
47.1 ± 17.3 %, p = 0.210). In addition, the value was
statistically similar between the DCM group and the
controls.
The mean trabeculated myocardial volume in INC
group (32.1 ± 13.8 mL) was 1.4 times lower than in
NINC group (45.1 ± 15.3 mL, p = 0.001), 1.9 times lower
than in DCMNC group (61.6 ± 25.5 mL, p < 0.001),
Fig. 5 Scattergrams of trabeculated LV volumes against late gadolinium enhancement (LGE) segments in the compacted myocardia of patients
with dilated cardiomyopathy (DCM) with hypertrabeculation and dilated cardiomyopathy with non-compaction (DCMNC). Simple linear regression
lines were applied to demonstrate relationships. Trabeculated LV volume was positively correlated with the number of LGE-positive segments
(Spearman ρ, 0.350; p = 0.008)
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1.3 times lower than in DCM group (41.9 ± 18.4 mL,
p = 0.01), and 1.3 times higher than in the controls (23.9 ±
6.9 mL, p = 0.007) (Table 2). In INC group, the trabecu-
lated myocardial volume index (18.9 ± 7.1 mL/m2) was 1.4
times lower than in NINC group (26.3 ± 9.2 mL/m2,
p = 0.001), 2.0 times lower than in DCMNC group (36.9 ±
15.6 mL/m2, p < 0.001), 1.3 times lower than in DCM
group (25.0 ± 10.4 mL/m2, p = 0.008) and 1.4 times
higher than in the control group (13.6 ± 3.7 mL/m2,
p = 0.001).
We were able to measure trabeculated LV volume in all
cases with an excellent interobserver reproducibility, and
the intra-class correlation coefficient (ICC) for inter-rater
reliability was 0.95 [95 % confidence interval (CI): 0.89–
0.98]. There was a slight bias (1.8 ± 4.7), but no tendency.
In addition, only one value out of 20 was outside the limits
of agreement. There was also excellent intraobserver re-
producibility. The ICC for intra-rater reliability was
strong, with a value of 0.98 (95 % CI: 0.96–0.99).
The intraclass coefficients for intraobserver variability
were 0.98 and 0.99 for LVESV and LVEDV, respectively,
while the intraclass coefficients for interobserver variability
were 0.95 and 0.88 for LVESV and LVEDV, respectively.
Value of the percentage of trabeculated LV volume and
semi-quantitative methods in LVNC diagnosis
The results of the ROC analysis for TV%, the apex/C
ratio, and the NC/septum ratio for LVNC diagnosis
using Jenni’s method for CMR classification or Petersen’s
CMR classification as the standard diagnostic criteria
were presented in Table 3 and Fig. 9. We also found that
TV% was positively correlated with Jenni’s (r = 0.484
[95 % CI: 0.349–0.60], p < 0.001) or Petersen’s CMR
criteria (r = 0.555 [95 % CI: 0.431–0.659]; p < 0.001) for
all groups. In four patients with ventricular arrhythmia,
Fig. 6 Scattergrams of trabeculated LV volume versus left ventricular
end-diastolic volume (LVEDV) (a) and left ventricular end-systolic
volume (LVESV) (b) in subjects from the isolated left ventricle
non-compaction (INC) group and the healthy control group.
Simple linear regression lines were applied to demonstrate
relationships. Trabeculated volume correlated positively with
LVEDV (Spearman ρ, 0.591; p = 0.006) and LVESV (Spearman
ρ, 0.618; p = 0.004)
Fig. 7 Scattergrams of trabeculated LV volume versus left ventricular
end-diastolic volume (LVEDV) (a), left ventricular end-systolic volume
(LVESV) (b), and left ventricular ejection fraction (LVEF) (c) in patients
from the dilated cardiomyopathy with hypertrabeculation (DCM)
and the dilated cardiomyopathy with non-compaction (DCMNC)
groups. Simple linear regression lines were applied to demonstrate
relationships. Trabeculated LV volume correlated positively with
LVEDV (Spearman ρ, 0.556; p < 0.001) and LVESV (Spearman ρ, 0.555;
p < 0.001) and negatively with LVEF (Spearman ρ, −0.385; p = 0.003)
Choi et al. Journal of Cardiovascular Magnetic Resonance  (2016) 18:24 Page 9 of 13
their mean TV% was 43.9 % (range, 33.6 %–54.8 %) and
their mean Petersen’s criteria measurement was 2.87
(range, 2.34–3.55).
The mean time required for the trabecular volume
measurement was about three minutes (range: two to
five minutes).
Discussion
The results of the present study can be summarized
as follows. Trabeculated LV volume was significantly
higher in INC patients as compared to healthy con-
trols and DCM patients, although there was some
overlap between the three groups. Patients with a
TV% above 35 % could be considered as LVNC cases.
Apex/C and NC/septum ratios could be supplemental
diagnostic tools for LVNC, while LGE findings were
rarely shown in the INC group. In DCMNC patients,
trabeculated LV volume was positively correlated with
LVEDV, LVESV, and the number of LGE segments,
and it was negatively correlated with LVEF.
Quantification of left ventricular trabeculation using CMR
The quantification of left ventricular trabeculation is an
ideal method to diagnose INC in that it reflects the total
volume of trabeculation and it does not depend on
particular slices selected from the CMR images. The quan-
tification of LV mass and volume with or without LV trabe-
culation has already been described and validated [19, 20].
Therefore, attempts to quantify trabeculation for the diag-
nosis of LVNC have already been performed by investiga-
tors [14, 21, 22]. The percentage of trabeculated LV mass
over 20 % was suggested as a diagnostic criterion for INC
by Jacquier et al. [14]. In addition, a maximal apical fractal
dimension over 1.3, which reflects the complexity of the
trabeculation, was proposed as a diagnostic criterion for
INC by Captur et al. [21]. Recently, Grothoff et al. sug-
gested that the percentage of non-compacted LV mass over
25 % should be the cutoff value for the diagnosis of LVNC,
which differs from Jacquier’s cutoff value [22]. The results
of our study were also inconsistent with these results.
In our study, TV% was significantly higher in the INC
group compared to the healthy control and DCM groups.
However, there was some overlap between the three
groups. Interestingly, TV% in the DCM group showed a
broad overlap with that of the INC group; these findings
are in contrast to the results of Jacquier et al. [14].
Supplementary diagnostic tools for LVNC
Petersen et al. excluded the measurement of the apex
(segment 17), because the apical compacted myocardium
is generally thinner than other segments, and its inclu-
sion would have led to an artificially high NC/C ratio
[13]. However, there are many studies that show hyper-
trabeculation is commonly involved in the apical
segment [13–15]. In our study, the apical segment was
involved in about 84 % of INC patients, while, in 6.2 %
(9/145) of subjects, the apex/C ratio could not be used
because of a lack of apical trabeculation.
Fig. 8 Distribution of the trabeculated myocardial volume over left
ventricular myocardial volume (%) for each group. The boxes extend
from the 25th percentile to the 75th percentile, and the whiskers
extend to 1.5 times the interquartile distance. Control, normal subjects
with hypertrabeculation; DCM, dilated cardiomyopathy with
hypertrabeculation; DCMNC, dilated cardiomyopathy with
non-compaction; INC, isolated LV non-compaction. P-values were
calculated in comparison with the values obtained in the LVNC
patients (*p < 0.013)
Table 3 Performance of the percentage of the trabeculated myocardial volume, the apex/C ratio, and the NC/septum ratio for left
ventricular non-compaction diagnosis from receiver operating characteristic curve analysis according to Jenni’s method for CMR and
Petersen’s CMR criteria
Refined CMR criteria Standard references Area under curve [CI] Specificity (%)[CI] Sensitivity (%)[CI]
TV (%LV) 34.6 % Jenni’s 0.843 [0.760-0.926] 89.7 [72.6 - 97.8] 66.1 [52.6 - 77.9]
32.3 % Petersen’s 0.894 [0.826-0.962] 90.3 [74.2 - 98.0] 79.0 [66.1 - 88.6]
Apex/C ratio 3.15 Jenni’s 0.820 [0.732-0.907] 93.1 [77.2 - 99.2] 69.5 [56.1 - 80.8]
3.11 Petersen’s 0.849 [0.769-0.930] 93.6 [78.6 - 99.2] 73.7 [60.3 - 84.5]
NC/septum ratio 1.27 Jenni’s 0.750 [0.638-0.863] 82.8 [64.2 - 94.2] 57.6 [44.1 - 70.4]
1.05 Petersen’s 0.892 [0.822-0.962] 80.7 [62.5 - 92.5] 87.7 [76.3 - 94.9]
C compacted, apex apical trabeculation thickness, NC non-compacted, septum septal wall thickness, TV (%LV) percentage of trabeculated myocardial volume over
left ventricular myocardial volume
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Fig. 9 Receiver operating characteristic curves, using patient classifications according to Jenni’s method for CMR (a) and Petersen’s CMR criteria
(b). The graphs describe the performance of the percentage of the trabeculated myocardial volume [TV (%LV)], the apex/C ratio, and the NC/septum
ratio for LVNC diagnosis. Refer to Table 3 for details
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In extremely non-compacted cases, compacted myo-
cardium was difficult to measure for the calculation of
various ratios, especially Petersen’s criteria. The thick-
ness of compact myocardium in the area of LVNC was
less than 2 mm in most patients (>66 %) except the
control group. The value of the non-compacted myocar-
dium to septal wall thickness might be useful in these cases.
Myocardial fibrosis in LVNC
LGE enables noninvasive assessment of cardiomyopathy
for the detection of myocardial fibrosis [23, 24]. In our
study, only 4.3 % of INC patients presented with LGE.
Our findings are consistent with other studies that also
noted a lack of LGE in LVNC patients [22, 25]. However,
there have also been studies that reported a high preva-
lence of LGE findings [26, 27]. According to Wan et al.
[27], LGE was present in 40 % of 47 patients with LVNC.
The reason for these discordances is unclear. Grothoff et
al. [22] pointed out that the contradictory LGE findings
might be caused partially by differences in imaging tech-
niques rather than by differences in the distribution of
age and LVEF. Burke et al. found from their pathological
study that all 14 of the cases included showed marked
endocardial fibrosis consistent with microscopic infarcts,
and that areas of subendocardial replacement fibrosis
were present in patients older than three weeks [28]. At
present, further studies with a larger sample size are
needed to investigate the pathophysiology and signifi-
cance of LGE in INC.
Dilated cardiomyopathy with LVNC
In the DCMNC group, we found that trabeculated LV
myocardial volume was positively correlated with
LVEDV and LVESV and negatively correlated with LVEF.
In the DCM group, however, there was no correlation
between trabeculated LV volume and LVESV or LVEF.
In our study, there was also a positive correlation
between trabeculated LV myocardial volume and the
number of LGE segments in the DCMNC group. It has
already been reported that myocardial fibrosis predicts a
poor prognosis in DCM patients [29, 30]. Masci et al.
also found that the absence of LGE at baseline is a
strong independent predictor of LV reverse remodeling
in idiopathic DCM patients [29]. Therefore, we conclude
that it is important to detect LVNC in DCM patients,
because DCMNC patients might have decreased LV
systolic function and an increased prevalence of LGE
findings.
Limitations
This study has some limitations that should be acknowl-
edged. First, it was a retrospective study. Second, be-
cause there was no standard reference for LVNC, Jenni’s
method and Petersen’s CMR criteria were used to define
our LVNC cases. Third, a selection bias may have been
introduced, as the study population included patients
presenting to a tertiary referral center. Fourth, although
we excluded the papillary muscles from the measure-
ment, we admit that poorly formed papillary muscle
could be counted as trabeculation. The patients’ genetic
factors were not considered in the LVNC diagnoses. A
genetic factor could help to provide more accurate diag-
noses for LVNC and would provide a more powerful
means of validating our method. We did not use
trabecula-dedicated software to measure the trabecular
myocardial volume excluding the blood cavity. However,
the manual measurement of trabecular volumes using
PACS or workstations provided by MR equipment
vendors was neither time-consuming nor difficult in our
study. Future studies are expected to use some
trabecula-specific software.
Conclusion
In this study, we used cardiac magnetic resonance
imaging to establish refined diagnostic criteria for
LVNC. As a quantitative approach, we have shown that
a TV% > 35 % of the LV myocardial volume is diagnostic
for LVNC with high specificity. In addition, as a
semi-quantitative approach, we propose a reproducible
method of using apex/C and NC/septum ratios for supple-
mental diagnostic criteria for LVNC.
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